`
`
`
`
`
`
`
`
`
`Paper __
`Filed: January 12, 2018
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________
`
`ACRUX DDS PTY LTD., ACRUX LIMITED,
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioners,
`
`v.
`
`KAKEN PHARMACEUTICAL CO., LTD. and
`VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
`Patent Owner.
`_______________
`
`Case IPR2017-001901
`Patent 7,214,506 B2
`_______________
`
`
`PETITIONERS’ MOTION TO SEAL
`
`
`
`
`
`1 Case IPR2017-01429 has been joined with the instant proceeding.
`
`
`
`Case IPR2017-00190
`Patent 7,214,506 B2
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54 and the Board’s Default Protective
`
`Order filed in these proceedings, Acrux DDS PTY Ltd., Acrux Limited, and
`
`Argentum Pharmaceuticals LLC (collectively, “Petitioners”) hereby move to seal
`
`Petitioners’ Reply in Support of Their Motion to Exclude Under 37 C.F.R. §
`
`42.64(c), filed concurrently herewith.
`
`The record of an inter partes review proceeding, including documents and
`
`things, is made available to the public, except as otherwise ordered. 37 C.F.R. §
`
`42.14. Despite the default rule of public availability, the Board will seal
`
`confidential information for “good cause,” because it is necessary to “strike a
`
`balance between
`
`the public’s
`
`interest
`
`in maintaining a complete and
`
`understandable file history and the parties’ interest in protecting truly sensitive
`
`information.” 37 C.F.R. § 42.54(a); 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012).
`
`It is Petitioners’ understanding that information in Kaken Exhibits 2093,
`
`2095, 2098 and 2099 has been designated as containing confidential information
`
`under the Board’s Default Protective Order.
`
`These documents have been filed under seal and are discussed in Petitioners’
`
`Reply in Support of Their Motion to Exclude Under 37 C.F.R. § 42.64(c),
`
`requiring the filing of the current motion to seal that document. Petitioners have
`
`no independent basis for the aforementioned documents to be sealed and thus make
`
`no assertion as to whether or not they contain confidential information.
`
`
`
`2
`
`
`
`Case IPR2017-00190
`Patent 7,214,506 B2
`Petitioners contacted Patent Owner regarding this Motion to Seal and Patent
`
`Owner did not oppose.
`
`
`
`
`
`
`
`
`
`Date: January 12, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`
`By:
`
`By:
`
`
`
`
`
`/E. Anthony Figg/
`E. Anthony Figg, Reg. No. 27,195
`Counsel for Acrux DDS Pty Ltd
`and Acrux Limited
`
`
`
`
`/Shannon M. Lentz/
`Shannon M. Lentz, Reg. No. 65,382
`Counsel for
`Argentum Pharmaceuticals LLC
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`CERTIFICATE OF SERVICE
`
`Case IPR2017-00190
`Patent 7,214,506 B2
`
`The undersigned certifies that a copy of the foregoing PETITIONER’S
`
`MOTION TO SEAL was served electronically via email on January 12, 2018, in
`its entirety on the following:
`
`
`John D. Livingstone
`john.livingstone@finnegan.com
`KakenIPR@finnegan.com
`Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
`271 17th Street, N.W., Suite 1400
`Atlanta, GA 30363-6209
`
`Naoki Yoshida
`naoki.yoshida@finnegan.com
`Anthony Hartmann
`Anthony.hartmann@finnegan.com
`Barbara R. Rudolph, Ph.D.
`barbara.rudolph@finnegan.com
`Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
`901 New York Ave., N.W.
`Washington, DC 20001-4413
`
`Toan P. Vo
`toan.vo@bausch.com
`Valeant Pharmaceuticals North America LLC
`1400 N. Goodman Street
`Rochester, NY 14609
`
`Teresa Stanek Rea
`TRea@Crowell.com
`Shannon M. Lentz
`SLentz@Crowell.com
`Crowell & Moring LLP
`Intellectual Property Group
`1001 Pennsylvania Ave, NW
`Washington, DC 20004-2595
`
`
`
`
`
`4
`
`
`
`Case IPR2017-00190
`Patent 7,214,506 B2
`
`
`
`By:
`
`Tyler C. Liu
`TLiu@agpharm.com
`Argentum Pharmaceuticals, LLC
`
`
`
`/E. Anthony Figg/
`E. Anthony Figg, Reg. No. 27,195
`Aydin H. Harston, Reg. No. 65,249
`ROTHWELL, FIGG, ERNST & MANBECK, P.C.
`607 14th St., N.W., Suite 800
`Washington, DC 20005
`Phone: 202-783-6040 | Fax: 202-783-6031
`
`
`
`
`
`
`
`
`
` Counsel for Acrux DDS Pty Ltd
`
`
`and Acrux Limited
`
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`